NeueHealth Inc · Q2 2024 earnings

Briefing

Reported solid Q2 2024 results, driven by focus on value-driven model and high-quality care, with positive Adjusted EBITDA for the second consecutive quarter.

NeueHealth reported solid Q2 2024 results with positive Adjusted EBITDA for the second consecutive quarter. The company is reaffirming Adjusted EBITDA guidance for the full year and expects to reach the high end of the guidance range for consumers served by year-end.

• Drove solid Q2 ‘24 results with continued focus on advancing value-driven model
• Delivered high-quality, consumer-centric care to all populations across the ACA Marketplace, Medicare, and Medicaid
• Delivered positive Adjusted EBITDA for the second consecutive quarter in 2024; reaffirming Adjusted EBITDA guidance for the full year
• Positioned for continued strong performance this year and beyond, expecting to reach high end of guidance range for consumers served by year-end

Headline financials

Revenue & EPS history

For 2024, NeueHealth expects revenue to be approximately $950 million, with NeueCare revenue around $320 million and NeueSolutions revenue around $640 million. The adjusted operating cost ratio is projected to be between 15% and 16% excluding corporate costs, and between 19% and 20% including corporate costs. Adjusted EBITDA is expected to be between $15 million and $25 million.